The U.S. Food and Drug Administration on Tuesday approved Sage Therapeutics Inc’s drug for postpartum depression, marking the first approval of a treatment specifically developed for the condition that affects a new mother’s ability to care for herself or her baby.
Latest posts by Reuters News (see all)
- Stocks and oil fall, yen rallies as Trump threatens to further escalate China trade war - August 23, 2019
- Oil spills into U.S.-China trade war, prices slump - August 23, 2019
- U.S. Justice Ginsburg treated for pancreatic cancer - August 23, 2019